Talk:Beta blocker: Difference between revisions
→Unsourced: r |
→Other Effects, Beta-adrenergic Receptors: new section |
||
Line 85: | Line 85: | ||
The "Other effects" section mentions beta-adrenergic mediated inhibition of melatonin secretion. It might be useful to discuss the differences in melatonin secretion inhibition between beta blockers. ―[[User:Biochemistry&Love|<span style="letter-spacing:1px"><span style="color:Teal">'''Bio'''</span><span style="color:seagreen">chemistry</span><span style="color:Teal">🙴</span><span style="color:firebrick">❤</span></span>]] 04:11, 18 October 2017 (UTC) |
The "Other effects" section mentions beta-adrenergic mediated inhibition of melatonin secretion. It might be useful to discuss the differences in melatonin secretion inhibition between beta blockers. ―[[User:Biochemistry&Love|<span style="letter-spacing:1px"><span style="color:Teal">'''Bio'''</span><span style="color:seagreen">chemistry</span><span style="color:Teal">🙴</span><span style="color:firebrick">❤</span></span>]] 04:11, 18 October 2017 (UTC) |
||
== Other Effects, Beta-adrenergic Receptors == |
|||
Proposed addition: "Because beta-adrenergic receptors are expressed across a diverse group of cancers, researchers are exploring ways to identify tumor types that would be responsive to beta blockers." Citation: [http://10.18632/oncoscience.357 10.18632/oncoscience.357] |
|||
This section on non-cardiological indications should be supported, although this citation is admittedly primary research. Do you think this adds reliable, valuable information to this article?[[User:Cglife.trummler|Cglife.trummler]] ([[User talk:Cglife.trummler|talk]]) 23:02, 14 November 2017 (UTC) |
Revision as of 23:02, 14 November 2017
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Beta blocker.
|
This is the talk page for discussing improvements to the Beta blocker article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
Archives: 1Auto-archiving period: 60 days |
Pharmacology C‑class Top‑importance | ||||||||||
|
Unsourced
Moved here per WP:PRESERVE as this is almost all unsourced. Per WP:BURDEN please do not restore without finding reliable sources, checking the content against them, and citing the sources.
- Examples
- Nonselective agents
Nonselective beta blockers display both β1 and β2 antagonism.[1]
- Propranolol[1]
- Bucindolol (has additional α1-blocking activity)[2]
- Carteolol[3]
- Carvedilol (has additional α1-blocking activity)[1]
- Labetalol (has additional α1-blocking activity)[1]
- Nadolol[1]
- Oxprenolol (has intrinsic sympathomimetic activity)[4]
- Penbutolol (has intrinsic sympathomimetic activity)[1]
- Pindolol (has intrinsic sympathomimetic activity)[1]
- Sotalol (not considered a "typical beta-blocker")[1]
- Timolol[1]
- β1-selective agents
β1-selective beta blockers are also known as cardioselective beta blockers.[1]
- Acebutolol (has intrinsic sympathomimetic activity, ISA)[1]
- Atenolol[1]
- Betaxolol[1]
- Bisoprolol[1]
- Celiprolol (has intrinsic sympathomimetic activity)[5]
- Metoprolol[1]
- Nebivolol[1]
- β2-selective agents
- β3-selective agents
- Comparative information
- Pharmacological differences
- Agents with intrinsic sympathomimetic action (ISA)
- Agents organized by lipid solubility (lipophilicity)[11]
- High lipophilicity: propranolol, labetalol
- Intermediate lipophilicity: metoprolol, bisoprolol, carvedilol, acebutolol, timolol, pindolol
- Low lipophilicity (also known as hydrophilic beta-blockers): atenolol, nadolol, and sotalol
- Agents with membrane stabilizing effect[12]
- Carvedilol, propranolol > oxprenolol > labetalol, metoprolol, timolol
- Indication differences
- Agents specifically labeled for cardiac arrhythmia
- Agents specifically labeled for congestive heart failure[1]
- Agents specifically labeled for glaucoma
- Agents specifically labeled for myocardial infarction[1]
- Atenolol, metoprolol (immediate release), propranolol (immediate release), timolol, carvedilol (after left ventricular dysfunction)
- Agents specifically labeled for migraine prophylaxis[17]
Propranolol is the only agent indicated for control of tremor, portal hypertension, and esophageal variceal bleeding, and used in conjunction with α-blocker therapy in phaeochromocytoma.[18]
References
- ^ a b c d e f g h i j k l m n o p q r s "Comparison of Oral Beta-Blockers". pharmacist.therapeuticresearch.com. Therapeutic Research Center. Retrieved 30 April 2017.
- ^ Rosendorff C (1993). "Beta-blocking agents with vasodilator activity". Journal of Hypertension. Supplement. 11 (4): S37–40. doi:10.1097/00004872-199306003-00009. PMID 8104240.
- ^ "CARTEOLOL". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
- ^ a b "oxprenolol". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
- ^ a b "Celiprolol". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
- ^ "Butaxamine". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
- ^ "ICI 118551 hydrochloride". abcam.com. Abcam plc. Retrieved 18 October 2017.
- ^ "SR 59230A". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
- ^ a b c Larochelle, Pierre; Tobe, Sheldon W.; Lacourcière, Yves (May 2014). "β-Blockers in Hypertension: Studies and Meta-analyses Over the Years". Canadian Journal of Cardiology. 30 (5): S16–S22. doi:10.1016/j.cjca.2014.02.012.
{{cite journal}}
:|access-date=
requires|url=
(help); no-break space character in|title=
at position 59 (help) - ^ Mulrow, edited by Detlev Ganten, Patrick J. (1990). Pharmacology of Antihypertensive Therapeutics. Berlin, Heidelberg: Springer Berlin Heidelberg. p. 523. ISBN 9783642742095.
{{cite book}}
:|access-date=
requires|url=
(help);|first1=
has generic name (help)CS1 maint: multiple names: authors list (link) - ^ Zipursky, Jonathan S.; Macdonald, Erin M.; Luo, Jin; Gomes, Tara; Mamdani, Muhammad M.; Paterson, J. Michael; Juurlink, David N. (June 2017). "Lipophilic β-Blockers and Suicide in the Elderly". Journal of Clinical Psychopharmacology. 37 (3): 381–384. doi:10.1097/JCP.0000000000000695. Retrieved 18 October 2017.
- ^ a b c d e Aronson, Jeffrey K (1 June 2008). "Changing beta-blockers in heart failure: when is a class not a class?". British Journal of General Practice. 58 (551): 387–389. doi:10.3399/bjgp08X299317.
{{cite journal}}
:|access-date=
requires|url=
(help) - ^ "BREVIBLOC (esmolol hydrochloride)". Baxter Healthcare Corporation.
{{cite web}}
:|access-date=
requires|url=
(help); Missing or empty|url=
(help) - ^ "BETAPACE AF (sotalol HCl)". Bayer HealthCare Pharmaceuticals Inc.
{{cite web}}
:|access-date=
requires|url=
(help); Missing or empty|url=
(help) - ^ "Announcement of Approval of Additional Indications for Onoact® 50 for Injection, Short-Acting Selective ß1 Blocker". www.evaluategroup.com. Evaluate Ltd. Retrieved 18 October 2017.
{{cite web}}
: no-break space character in|title=
at position 52 (help) - ^ "DailyMed - METIPRANOLOL- metipranolol solution/ drops". dailymed.nlm.nih.gov. NIH. Retrieved 18 October 2017.
- ^ "Drugs to Prevent Migraine in Adults". pharmacist.therapeuticresearch.com. Therapeutic Research Center. Retrieved 30 April 2017.
- ^ Cite error: The named reference
Rossi
was invoked but never defined (see the help page).
@Jytdog: I've finished the necessary citing and have moved the material over. Thank you for bringing this important issue to our attention.―Biochemistry🙴❤ 04:09, 18 October 2017 (UTC)
- Thanks for taking care of that! So much work! Jytdog (talk) 05:17, 18 October 2017 (UTC)r
Expand on Other Effects
The "Other effects" section mentions beta-adrenergic mediated inhibition of melatonin secretion. It might be useful to discuss the differences in melatonin secretion inhibition between beta blockers. ―Biochemistry🙴❤ 04:11, 18 October 2017 (UTC)
Other Effects, Beta-adrenergic Receptors
Proposed addition: "Because beta-adrenergic receptors are expressed across a diverse group of cancers, researchers are exploring ways to identify tumor types that would be responsive to beta blockers." Citation: 10.18632/oncoscience.357
This section on non-cardiological indications should be supported, although this citation is admittedly primary research. Do you think this adds reliable, valuable information to this article?Cglife.trummler (talk) 23:02, 14 November 2017 (UTC)